搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Methanopyrus kandleri UPF0095 protein MK0617 (MK0617) CSB-YP851668MSI
CSB-EP851668MSI
CSB-BP851668MSI
CSB-MP851668MSI
CSB-EP851668MSI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanopyrus kandleri Fibrillarin-like rRNA/tRNA 2'-O-methyltransferase (flpA) CSB-YP851669MSI
CSB-EP851669MSI
CSB-BP851669MSI
CSB-MP851669MSI
CSB-EP851669MSI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanopyrus kandleri Translation initiation factor 1A (eIF1A) CSB-YP851670MSI
CSB-EP851670MSI
CSB-BP851670MSI
CSB-MP851670MSI
CSB-EP851670MSI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanopyrus kandleri Transcription factor E (tfe) CSB-YP851671MSI
CSB-EP851671MSI
CSB-BP851671MSI
CSB-MP851671MSI
CSB-EP851671MSI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanopyrus kandleri 3-dehydroquinate dehydratase (aroD) CSB-YP851672MSI
CSB-EP851672MSI
CSB-BP851672MSI
CSB-MP851672MSI
CSB-EP851672MSI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanopyrus kandleri 30S ribosomal protein S27e (rps27e) CSB-YP851673MSI
CSB-EP851673MSI
CSB-BP851673MSI
CSB-MP851673MSI
CSB-EP851673MSI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanopyrus kandleri Ribonuclease P protein component 3 (rnp3) CSB-YP851674MSI
CSB-EP851674MSI
CSB-BP851674MSI
CSB-MP851674MSI
CSB-EP851674MSI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanopyrus kandleri DNA-directed RNA polymerase subunit P (rpoP) CSB-YP851675MSI
CSB-EP851675MSI
CSB-BP851675MSI
CSB-MP851675MSI
CSB-EP851675MSI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanopyrus kandleri Putative cobalt-precorrin-6A synthase [deacetylating] (cbiD) CSB-YP851676MSI
CSB-EP851676MSI
CSB-BP851676MSI
CSB-MP851676MSI
CSB-EP851676MSI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanopyrus kandleri Putative (R)-citramalate synthase CimA (cimA), partial CSB-YP851677MSI
CSB-EP851677MSI
CSB-BP851677MSI
CSB-MP851677MSI
CSB-EP851677MSI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanopyrus kandleri UPF0284 protein MK0224 (MK0224) CSB-YP851678MSI
CSB-EP851678MSI
CSB-BP851678MSI
CSB-MP851678MSI
CSB-EP851678MSI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanopyrus kandleri UPF0280 protein MK0206 (MK0206) CSB-YP851679MSI
CSB-EP851679MSI
CSB-BP851679MSI
CSB-MP851679MSI
CSB-EP851679MSI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanopyrus kandleri Putative ABC transporter ATP-binding protein MK0182 (MK0182) CSB-YP851680MSI
CSB-EP851680MSI
CSB-BP851680MSI
CSB-MP851680MSI
CSB-EP851680MSI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanopyrus kandleri Glucosamine--fructose-6-phosphate aminotransferase [isomerizing] (glmS), partial CSB-YP851681MSI
CSB-EP851681MSI
CSB-BP851681MSI
CSB-MP851681MSI
CSB-EP851681MSI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanopyrus kandleri DNA-directed RNA polymerase subunit L (rpoL) CSB-YP851682MSI
CSB-EP851682MSI
CSB-BP851682MSI
CSB-MP851682MSI
CSB-EP851682MSI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanopyrus kandleri 50S ribosomal protein L15P (rpl15p) CSB-YP851683MSI
CSB-EP851683MSI
CSB-BP851683MSI
CSB-MP851683MSI
CSB-EP851683MSI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanopyrus kandleri UPF0254 protein MK0012 (MK0012) CSB-YP851684MSI
CSB-EP851684MSI
CSB-BP851684MSI
CSB-MP851684MSI
CSB-EP851684MSI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus furiosus 30S ribosomal protein S3Ae (rps3Ae) CSB-YP851685FHW
CSB-EP851685FHW
CSB-BP851685FHW
CSB-MP851685FHW
CSB-EP851685FHW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus furiosus Preprotein translocase subunit SecE (secE), partial CSB-YP851686FHW
CSB-EP851686FHW
CSB-BP851686FHW
CSB-MP851686FHW
CSB-EP851686FHW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pyrococcus furiosus Protein-L-isoaspartate O-methyltransferase (pcm) CSB-YP851687FHW
CSB-EP851687FHW
CSB-BP851687FHW
CSB-MP851687FHW
CSB-EP851687FHW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>